Mass spectrometry (MS) enables rapid and sensitive qualitative and quantitative analyses of biomolecules (proteins, peptides, oligosaccharides, lipids, DNA, and RNA), drugs, and metabolites. MS has become an essential tool in modern biomedical research, including the analysis of DNA methylation. DNA methylation has been reported in many cancers, suggesting that it can be utilized as an early biomarker to improve the early diagnosis rate. Using matrix-assisted laser desorption/ionization time-of-flight MS and MassCLEAVE reagent, we compared Nell-1 hypermethylation levels among tumor tissues, paracarcinoma tissues, and normal tissues from gastric cancer patients. Almost 80% of the CpG sites in the amplicons produced were covered by the analysis. Our results indicate a significant difference in methylation status between gastric cancer tissue (a higher level) and normal tissue. The same trend was identified in gastric cancer tissue versus paracarcinoma tissue. We also detected lower relative expression of Nell-1 by real-time PCR. Furthermore, immunohistochemical analyses revealed that Nell-1 staining was less intense in cancer tissue relative to normal tissue and that the tumor cells had spread to the muscle layer. These findings may serve as a guide for the early diagnosis of gastric cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452250 | PMC |
http://dx.doi.org/10.1155/2015/136941 | DOI Listing |
J Biochem Mol Toxicol
February 2025
Department of Anorectal Center, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Circular RNA (CircRNA)s, a newly discovered type of noncoding RNAs, have been found to play a role in controlling the development and aggressiveness of tumors. Abnormal control of circRNA has been observed in various types of human cancers, including bladder cancer, hepatocellular carcinoma (HCC), breast cancer, and gastric cancer (GC). CircRNAs possess binding sites for microRNAs (miRNAs) and function as miRNA sponges in posttranscriptional regulation.
View Article and Find Full Text PDFDig Endosc
January 2025
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Clin Pharmacol Ther
January 2025
Gilead Sciences, Inc., Foster City, California, USA.
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug-drug interactions between obeldesivir and substrates or inhibitors of cytochrome P450 and drug transporters in healthy participants. When obeldesivir was tested as a precipitant, pharmacokinetic parameter point estimates for midazolam (CYP3A4 inhibition/induction), caffeine (CYP1A2 inhibition), and metformin (organic cation transporter 1 inhibition) exposures were within 80-125% no-effect bounds representing the interval within which a systemic exposure change does not warrant clinical action based on EMA/FDA guidance.
View Article and Find Full Text PDFmSphere
January 2025
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
is a major causative agent in several upper gastroduodenal tract diseases, including gastric cancer. The development of methods to genetically manipulate by natural transformation has allowed a greater understanding of its biology and role in these diseases. Nevertheless, the transformation methods used for are time-consuming, requiring growth of these fastidious and slow-growing bacteria from -80°C stocks.
View Article and Find Full Text PDFJ Asian Nat Prod Res
January 2025
Department of Pharmaceutical Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
The 3-O-(4'-imidazole)-12-en-olean-28-amide derivatives to through modification the C-3 and C-28 of the natural product oleanolic acid were prepared, and their structures were confirmed by MS,H NMR and C NMR. The antitumor activities of these compounds against breast cancer MCF-7 and gastric cancer SGC7901 cells were determined by MTT assay. Cell tests showed that the antitumor activities of compound exhibited significant antitumor activity which was equivalent to the positive control drug nilotinib, and the affinity was verified by molecular dynamics experiment .
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!